Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
What adjuvant therapy, if any, would you offer for a young fit patient with stage IB lung adenocarcinoma harboring an EGFR A763_Y764insFQEA who received no prior therapy?
Related Questions
How would you approach treatment for patients with limited stage small cell lung cancer (SCLC) who, after induction chemotherapy with carboplatin/etoposide, develop a new contralateral lung nodule confirmed as SCLC, while their primary tumor shows a partial response?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
Is there a role for surgical debulking, local RT or subsequent line of chemotherapy for a patient with stable malignant thymoma but active myasthenia gravis?
How would you approach local therapy (surgery or RT) in a patient with radiographic complete response after chemoimmunotherapy for non-small-cell lung cancer?
Would you use Razor Genomics RiskReveal molecular testing results to guide making recommendations for surgical adjuvant chemotherapy for Stage IA,IB & II non-squamous NSCLCA ?
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
What is your approach to obtain tissue diagnosis for a patient with a lung primary and spine metastasis?
What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?
Do you tell your patients with epithelioid subtype mesothelioma following gross resection and adjuvant cis/pemetrexed that they have completed "curative intent" treatment?
How often, if ever, do patients with initially negative targetable mutation workup become positive later in recurrent lung cancer?
